GO:0004662 CAAX-protein geranylgeranyltransferase activity

GO:0004662, CAAX-protein geranylgeranyltransferase activity, is a molecular function that catalyzes the transfer of a geranylgeranyl group from geranylgeranyl diphosphate to a cysteine residue in the C-terminal CAAX motif of a protein substrate. This post-translational modification, called geranylgeranylation, creates a thioether linkage between the C-1 atom of the geranylgeranyl group and the cysteine that is fourth from the protein C-terminus. The reaction is a key step in the prenylation pathway and is carried out by the enzyme protein geranylgeranyltransferase type I (GGTase-I). The CAAX motif consists of a cysteine (C), two aliphatic amino acids (A1 and A2), and a variable terminal residue (X); for GGTase-I, X is preferably leucine and A2 should not be aromatic. This substrate preference distinguishes GGTase-I from farnesyltransferase, which prefers methionine or other residues at X. Because geranylgeranylation increases hydrophobicity, it enables target proteins to associate with cellular membranes, a requirement for their roles in signal transduction, cytoskeletal organization, and vesicle trafficking. Researchers study GO:0004662 to understand how cells control the localization and activity of key regulatory proteins, and to explore therapeutic strategies that target prenylation in diseases such as cancer [1,2].

According to the Gene Ontology, GO:0004662 is defined as the catalysis of the reaction: geranylgeranyl diphosphate + protein-cysteine = S-geranylgeranyl-protein + diphosphate. This reaction forms a thioether linkage between the C-1 atom of the geranylgeranyl group and a cysteine residue fourth from the C-terminus of the protein. The protein substrates have the C-terminal sequence CA1A2X, where the terminal residue X is preferably leucine and A2 should not be aromatic. Known substrates include most gamma subunits of heterotrimeric G proteins and Ras-related GTPases such as members of the Ras and Rac/Rho families. The activity is also known as geranylgeranyltransferase type I activity, GGTase-I activity, and protein geranylgeranyltransferase type I.

GO:0004662 is important because geranylgeranylation is a critical post-translational modification that controls the membrane targeting and function of many signaling proteins. The substrates of GGTase-I include Ras-related GTPases and heterotrimeric G protein gamma subunits, which are central to cell growth, differentiation, and cytoskeletal regulation. Dysregulation of these proteins is linked to cancer and other diseases, making the enzyme an attractive target for therapeutic intervention [1,2]. Understanding the substrate specificity and regulation of this activity provides insight into how cells organize signal transduction and how prenylation inhibitors might be used in the clinic.

The following genes and proteins are directly involved in or regulated by CAAX-protein geranylgeranyltransferase activity, based on published literature [1,2].

The activity of CAAX-protein geranylgeranyltransferase is regulated at multiple levels. Substrate availability and the expression levels of the enzyme subunits CDC43 and RAM2 influence the rate of geranylgeranylation. Additionally, the prenylation pathway can be modulated by the availability of geranylgeranyl diphosphate, which is synthesized via the mevalonate pathway. Competitive inhibitors of GGTase-I, such as GGTI compounds, can block the enzyme activity and have been used to study its role in cells. Furthermore, cross-talk between farnesyltransferase and GGTase-I can affect substrate specificity and the overall prenylation status of proteins.

Geranylgeranylation of Ras and Rho family GTPases is critical for their oncogenic signaling, and inhibition of GGTase-I has been explored as an anticancer strategy. Many cancer cells depend on geranylgeranylated proteins for proliferation and survival, making GO:0004662 a potential therapeutic target.

Proper geranylgeranylation of Rho GTPases is important for neuronal development and survival, and dysregulation of prenylation has been implicated in neurodegenerative conditions. However, direct evidence linking GGTase-I mutations to neurodegeneration is limited, and further studies are needed.

Geranylgeranylation of Rho GTPases is required for immune cell migration and activation, and GGTase-I inhibitors can modulate inflammatory responses. This suggests that GO:0004662 may play a role in autoimmune and inflammatory diseases.

In vitro assays using recombinant GGTase-I and radiolabeled geranylgeranyl diphosphate can measure the transfer of the lipid to peptide substrates corresponding to CAAX motifs. These assays help determine substrate specificity and kinetic parameters.

Metabolic labeling with radioactive mevalonate or clickable geranylgeranyl analogs followed by immunoprecipitation can assess the geranylgeranylation status of specific proteins in cells. This approach is useful for studying the effects of inhibitors or mutations.

Mass spectrometry-based proteomics can identify geranylgeranylated proteins and map modification sites, providing a global view of GGTase-I substrates. This method is powerful for discovering novel targets and understanding pathway crosstalk.

CRISPR knockout or point mutation of GGTase-I subunits or substrate CAAX motifs can reveal functional consequences in cell models. Such screens help link GO:0004662 to specific cellular phenotypes and diseases.

Researchers studying CAAX-protein geranylgeranyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and knock-in models.

GO:0004662, CAAX-protein geranylgeranyltransferase activity, is a fundamental enzymatic function that controls the lipid modification of key signaling proteins. Its substrates, including Ras and Rho family GTPases, are central to cell growth, cytoskeletal dynamics, and disease. Understanding the mechanism, regulation, and substrate specificity of this activity provides a foundation for therapeutic targeting in cancer and other conditions. EDITGENE offers comprehensive CRISPR services to facilitate research on this important pathway.